Purification of Staphylococcus aureus type 5 capsular saccharides

Patent metadata

Field	Value
Publication number	US-9060965-B2
Application number	US-201013504920-A
Country	US
Kind code	B2
Filing date	Nov 1, 2010
Priority date	Oct 30, 2009
Publication date	Jun 23, 2015
Grant date	Jun 23, 2015

Abstract

The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.

First claim

The invention claimed is:

1. A method for releasing capsular polysaccharide from S. aureus type 5 cells, comprising the step of releasing capsular polysaccharide by treating the cells with acid, wherein the treatment produces capsular polysaccharide with an average molecular weight of between 2 kDa and 3500 kDa, the cells were not autoclaved prior to treating with acid, and the method for releasing does not include treatment with lysostaphin, wherein the acid treatment results in the capsular polysaccharide having a degree of O-acetylation between 60-100%.

2. The method according to claim 1 , wherein the cells are in the form of a wet cell paste or are suspended in an aqueous medium.

3. The method according to claim 1 , wherein the acid treatment is carried out using acetic acid.

4. The method according to claim 1 , wherein the method further comprises a step of neutralisation.

5. The method according to claim 1 , wherein the method further comprises a step of centrifugation of the cells and collection of the polysaccharide-containing supernatant.

6. A process for purifying capsular polysaccharide from S. aureus type 5 cells comprising the method according to claim 1 further comprising a step selected from the group consisting of treatment of the capsular polysaccharide with DNase and/or RNase, treatment of the capsular polysaccharide with mutanolysin, diafiltration, anion exchange chromatography, gel filtration, concentration of the polysaccharide, sterile filtration, and combinations thereof.

7. The process according to claim 6 , wherein the process further comprises a step of treatment of the capsular polysaccharide with DNase and/or RNase.

8. The process according to claim 6 , wherein the process further comprises a step of treatment of the capsular polysaccharide with mutanolysin.

9. The process according to claim 6 , wherein the process further comprises a step of diafiltration.

10. The process according to claim 9 , wherein the diafiltration is tangential flow filtration.

11. The process according to claim 6 , wherein the process further comprises a step of anion exchange chromatography.

12. The process according to claim 6 , wherein the process further comprises a step of gel filtration.

13. The process according to claim 6 , wherein the process further comprises a step of concentration of the polysaccharide.

14. The process according to claim 6 , wherein the process further comprises a step of depolymerisation of the purified polysaccharide to form an oligosaccharide.

15. The process according to claim 6 , wherein the process further comprises a step of sterile filtration.

16. The process according to claim 6 , wherein the process provides a composition comprising the polysaccharide and a level of peptidoglycan contamination that is less than 5% by weight peptidoglycan relative to the total weight of the polysaccharide.

17. The process according to claim 16 , wherein the level of peptidoglycan contamination is about 2%.

18. The process according to claim 6 , wherein the process provides a composition comprising the polysaccharide and a level of protein contamination that is less than 5% by weight protein relative to the total weight of the polysaccharide.

19. The process according to claim 6 , wherein the process provides a composition comprising the polysaccharide and a level of nucleic acid contamination that is less than 1% by weight nucleic acid relative to the total weight of the polysaccharide.

20. The process according to claim 6 , wherein the process further comprises a step of conjugation to a carrier molecule.

Assignees

• Costantino Paolo
• Romano Maria Rosaria
• Berti Francesco
• Glaxosmithkline Biolog Sa

Inventors

• Costantino Paolo
• Romano Maria Rosaria
• Berti Francesco

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title

• C07H1/08 Primary

  from natural products · CPC title